FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2736707568> ?p ?o ?g. }

• W2736707568 abstract "2547 Background: Bringing precision medicine to cancer patients remains a challenge. For many cancers, the relative contribution of tumor type, mutations or CNV to drug sensitivity remains unknown. In addition, drug access is generally limited to the labeled indication, bypassing rarer disease subgroups for which large trials are not feasible. An innovative trial that facilitates drug access, whilst systematically analyzing treatment outcomes and biomarkers, could help overcome these challenges. Methods: We designed a prospective, non randomized clinical trial in which patients with advanced cancer are treated with targeted or immunotherapy matched to their tumor profile, defined by genetic aberration, microsatellite instability (MSI) or high mutational load (HML). Upon a mandatory pre-treatment tumor biopsy for biomarker research, patients are enrolled in multiple parallel cohorts, each defined by study drug, histologic tumor type and molecular tumor profile. Efficacy is analyzed per cohort, enrolling 8 patients in stage I and 16 more in stage II if ≥1 response is observed in stage I. Study endpoints include objective tumor response (CR or PR), stable disease (SD) at 16 weeks and grade≥3 adverse events. The DRUP is registered at ClinicalTrials.gov (NCT02925234). Results: Since start of recruitment in Sep 2016, 76 patients have been submitted for review (mean per month 15, range 8-17) and 16 (21%) have started treatment in 10 different cohorts, directed at either ATM (n = 1; breast cancer), BRAF (n = 2; salivary duct carcinoma and ACUP), BRCA (n = 1; breast cancer), ERBB2 (n = 2; CRC), HML (n = 2; prostate and CRC), MSI (n = 5; CRC, GBM and urothelial carcinoma), RET (n = 1; NSCLC) or RAS-RAF wt (n = 2; SCC and sarcoma). Out of the 7 patients for whom response evaluation is available, PR (n = 2) or SD at 16 weeks (n = 1) was observed in 3 (43%). Thirteen study drugs (supplied by 6 pharmaceutical companies) are currently available, 6 more are expected soon. Conclusions: Execution of a nationwide multidrug precision oncology trial is feasible. It contributes to oncologists’ education on molecularly targeted therapies and to identification of early signs of activity in rare cancer subsets. Data sharing with similar studies such as TAPUR and CAPTUR will help to enlarge cohorts and affirm conclusions. Clinical trial information: NCT02925234." @default.
• W2736707568 created "2017-07-31" @default.
• W2736707568 creator A5010531755 @default.
• W2736707568 creator A5051650713 @default.
• W2736707568 creator A5058463503 @default.
• W2736707568 creator A5060207753 @default.
• W2736707568 creator A5063282762 @default.
• W2736707568 creator A5069105295 @default.
• W2736707568 creator A5076064359 @default.
• W2736707568 creator A5076740454 @default.
• W2736707568 creator A5085853714 @default.
• W2736707568 creator A5088673015 @default.
• W2736707568 date "2017-05-20" @default.
• W2736707568 modified "2023-09-29" @default.
• W2736707568 title "The Drug Rediscovery Protocol (DRUP)." @default.
• W2736707568 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.2547" @default.
• W2736707568 hasPublicationYear "2017" @default.
• W2736707568 type Work @default.
• W2736707568 sameAs 2736707568 @default.
• W2736707568 citedByCount "0" @default.
• W2736707568 crossrefType "journal-article" @default.
• W2736707568 hasAuthorship W2736707568A5010531755 @default.
• W2736707568 hasAuthorship W2736707568A5051650713 @default.
• W2736707568 hasAuthorship W2736707568A5058463503 @default.
• W2736707568 hasAuthorship W2736707568A5060207753 @default.
• W2736707568 hasAuthorship W2736707568A5063282762 @default.
• W2736707568 hasAuthorship W2736707568A5069105295 @default.
• W2736707568 hasAuthorship W2736707568A5076064359 @default.
• W2736707568 hasAuthorship W2736707568A5076740454 @default.
• W2736707568 hasAuthorship W2736707568A5085853714 @default.
• W2736707568 hasAuthorship W2736707568A5088673015 @default.
• W2736707568 hasConcept C142724271 @default.
• W2736707568 hasConcept C204787440 @default.
• W2736707568 hasConcept C2780035454 @default.
• W2736707568 hasConcept C2780385302 @default.
• W2736707568 hasConcept C71924100 @default.
• W2736707568 hasConcept C98274493 @default.
• W2736707568 hasConceptScore W2736707568C142724271 @default.
• W2736707568 hasConceptScore W2736707568C204787440 @default.
• W2736707568 hasConceptScore W2736707568C2780035454 @default.
• W2736707568 hasConceptScore W2736707568C2780385302 @default.
• W2736707568 hasConceptScore W2736707568C71924100 @default.
• W2736707568 hasConceptScore W2736707568C98274493 @default.
• W2736707568 hasLocation W27367075681 @default.
• W2736707568 hasOpenAccess W2736707568 @default.
• W2736707568 hasPrimaryLocation W27367075681 @default.
• W2736707568 hasRelatedWork W2007523256 @default.
• W2736707568 hasRelatedWork W2076647600 @default.
• W2736707568 hasRelatedWork W2168933068 @default.
• W2736707568 hasRelatedWork W2190879643 @default.
• W2736707568 hasRelatedWork W2247705343 @default.
• W2736707568 hasRelatedWork W2811254165 @default.
• W2736707568 hasRelatedWork W2896686318 @default.
• W2736707568 hasRelatedWork W3155932657 @default.
• W2736707568 isParatext "false" @default.
• W2736707568 isRetracted "false" @default.
• W2736707568 magId "2736707568" @default.
• W2736707568 workType "article" @default.